SEOUL, South Korea
GI Innovation, an innovative new drug development company, announced on February 23 that it has signed a biomarker joint research MoU with CellKey, a Glycoprotein biomarker development company, to develop next-generation innovative immuno-oncology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220224005378/en/
GI Innovation signed MoU with CellKey for biomarker joint research to develop next-generation innovative immuno-oncology. (from left) Ji-Soo Kim director, Na-Ri Yun VP, Myoung-Ho Jang Chairman of GI Innovation and Nam-Yong Lee CEO, Sang-Yong Lee COO, Kwang-Hoe Kim Head of Bio-R&D center of CellKey participated in the MoU ceremony. Under the MoU, GI Innovation will progress joint biomarker research to develop next-generation protein and antibody drugs using GI Innovation’s bispecific fusion protein development platform GI-SMART™ and CellKey’s AI-powered biomarker discovery platform SpAC9 Pipeline. (Photo: Business Wire)
The MoU ceremony was held in GI Innovation’s head office and Myoung-Ho Jang Chairman, Na-Ri Yun VP, Ji-Soo Kim director of GI Innovation and Nam-Yong Lee CEO, Kwang-Hoe Kim Head of Bio-R&D center, Sang-Yong Lee COO of CellKey have attended.
Under the MoU, GI Innovation will progress joint biomarker research to develop next-generation protein and antibody drugs using GI Innovation’s bispecific fusion protein development platform GI-SMART™ and CellKey’s AI-powered biomarker discovery platform SpAC9 Pipeline. In addition, both companies will progress jointly published thesis, academic publication, research business, etc.
A biomarker is biological index that can sense symptoms in the body using protein, DNA, RNA, metabolite, etc. The more the multiple panels are constructed the more possibilities are to raise accuracy and diagnose early cancer.
In particular, AI and cloud-powered SpAC9 Pipeline of CellKey enables the discovery of the most optimal multi-biomarker panels, consisting of glycoproteins and proteins, up to 100 times faster than with conventional analysis methods.
With this strategic partnership, both companies expect that GI Innovation will predict drug responses on GI Innovation’s immuno-oncology and reinforce the reliability and efficacy of treatment through the biomarker discovery that can monitor treatment effects. CellKey also expects to improve upon the effects of personalized treatments and cancer diagnostic biomarker business.
Myoung-Ho Jang, Chairman of GI Innovation said, “By collaborating with Cellkey that has SpAC9 Pipeline, an innovative proteomics biomarker development platform, the opportunities for successful new drug development are increased. We will do our best to choose prime target patients in the clinical trial stage through the early discovery of biomarker.”
Nam-Yong Lee, CEO of CellKey said, “I believe we can innovatively improve the effectiveness of cancer treatments through this joint research with GI Innovation who develops immuno-oncology drugs with world-class R&D capabilities. This collaboration can create various business opportunities in the market of antibody drugs and precision medicine.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005378/en/
CONTACT
GI Innovation
Eun-Hee Rho
selly215@gi-innovation.com
